PRESS RELEASE

Q2 2020 — Press release

Q2 2020PDF · 17 pages439 KB
JOHNSON & JOHNSON REPORTS 2020 SECOND-QUARTER RESULTS:
• 	Sales of $18.3 billion reflecting a decline of 10.8%, operational decline of 9.0%* and adjusted
operational decline of 8.8%*, primarily driven by the negative impact of the COVID-19 pandemic
• 	EPS of $1.36 decreased 34.6%; adjusted EPS of $1.67 decreased 35.3%*; 2019 included gain
from sale of Advanced Sterilization Products (ASP) business
• 	Company increasing Full Year Sales and EPS guidance
New Brunswick, N.J. (July 16, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter
2020. “Our second quarter results reflect the impact of COVID-19 and the enduring strength of our Pharmaceutical
business, where we saw continued growth even in this environment,” said Alex Gorsky, Chairman and Chief Executive
Officer. “Thanks to the tireless work of our colleagues around the world and our broad range of capabilities, we continue
to successfully navigate the external landscape, and we remain focused on advancing the development of a vaccine
to help address this pandemic and save lives.“ Mr. Gorsky continued, “We are bringing together our best minds, our
global footprint and our sophisticated supply chain technology to deliver on our commitment to provide the vaccine on
a not-for-profit basis for emergency pandemic use, globally. We know the need is urgent, and every day we commit to
doing our part to find a solution for the global good.”
OVERALL FINANCIAL RESULTS:
1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational currency
4 Excludes intangible amortization expense and special items
($ in Millions, except EPS) 	2020 	2019 	% Change
Reported Sales 	18,336	$ 	20,562	$ 	(10.8)%
Net Earnings 	3,626 	5,607 	(35.3)%
EPS (diluted) 	1.36	$ 	2.08	$ 	(34.6)%
Non-GAAP*
($ in Millions, except EPS) 	2020 	2019 	% Change
Operational Sales1,2 	(9.0)%
Adjusted Operational Sales1,3 	(8.8)%
Adjusted Net Earnings1,4 	4,446 	6,950 	(36.0)%
Adjusted EPS (diluted)1,4 	1.67	$ 	2.58	$ 	(35.3)%
SECOND QUARTER
SECOND QUARTER

-- 1 of 17 --

2
REGIONAL SALES RESULTS:
1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational currency
Note: values may have been rounded
SEGMENT SALES RESULTS:
1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational currency
Note: values may have been rounded
Adjusted
($ in Millions) 1
Adjusted
2020 1
Adjusted
2019 1
Adjusted
Reported2
Adjusted
Operational 1,2
Adjusted
Currency1
Adjusted
Operational 1,3
Consumer Health 	3,296	$ 	3,544	$ 	(7.0)% 	(3.6) 	(3.4) 	(3.4)
Pharmaceutical 	10,752 	10,529 	2.1% 	3.9 	(1.8) 	3.9
Medical Devices 	4,288 	6,489 	(33.9)% 	(32.7) 	(1.2) 	(32.5)
Worldwide 	18,336	$ 	20,562	$ 	(10.8)% 	(9.0) 	(1.8) 	(8.8)
% Change	SECOND QUARTER

-- 2 of 17 --

3
SEGMENT COMMENTARY:
Consumer Health
Consumer Health worldwide operational sales, excluding the net impact of acquisitions and divestitures, declined by
3.4%* as results were negatively impacted by the COVID-19 pandemic most notably reflected in skin health and beauty
care products, followed by women’s health care products and international baby care products. Partially offsetting this
impact was growth in over-the-counter products including TYLENOL analgesics; digestive health products and
ZARBEE’S NATURALS; and LISTERINE mouthwash in oral care products. 	Both over-the-counter and oral care
products were positively impacted by COVID-19.
Pharmaceutical
Pharmaceutical worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 3.9%*
driven by STELARA (ustekinumab), a biologic for the treatment of a number of immune-mediated inflammatory
diseases, DARZALEX (daratumumab), for the treatment of multiple myeloma, IMBRUVICA (ibrutinib), an oral, once-
daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer, ERLEADA
(apalutamide), a next-generation androgen receptor inhibitor for the treatment of patients with prostate cancer,
TREMFYA (guselkumab), a biologic for the treatment of adults living with moderate to severe plaque psoriasis,
UPTRAVI (selexipag), an oral prostacyclin receptor agonist used to treat pulmonary arterial hypertension and reduce
hospitalization, INVEGA SUSTENNA/XEPLION/INVEGA TRINZA/TREVICTA (paliperidone palmitate), long-acting,
injectable atypical antipsychotics for the treatment of schizophrenia in adults, and OPSUMIT (macitentan), an oral
endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension to delay disease
progression. This growth was partially offset by the negative impact of COVID-19 as well as biosimilar and generic
competition, with declines primarily in REMICADE (infliximab), a biologic approved for the treatment of a number of
immune-mediated inflammatory diseases, international VELCADE (bortezomib), a proteasome inhibitor for the
treatment of multiple myeloma, and ZYTIGA (abiraterone acetate), an oral, once-daily medication for use in
combination with prednisone for the treatment of metastatic castration-resistant prostate cancer.
Medical Devices
Medical Devices worldwide operational sales, excluding the net impact of acquisitions and divestitures, declined by
32.5%* primarily driven by the negative impact of the COVID-19 pandemic and the associated deferral of medical
procedures to our Surgery, Orthopaedics, Vision and Interventional Solutions businesses.

-- 3 of 17 --

4
NOTABLE NEW ANNOUNCEMENTS IN THE QUARTER:
The information contained in this section should be read in conjunction with Johnson & Johnson’s other disclosures
filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on
Form 10-Q and Annual Reports on Form 10-K. Copies of these filings are available online at www.sec.gov,
www.jnj.com or on request from Johnson & Johnson. The reader is also encouraged to review all other news
releases available online in the Investors section of the Company’s website at news releases.
Regulatory
Approvals
TREMFYA (guselkumab) – U.S. Food and Drug Administration (FDA) Approves for
Adult Patients with Active Psoriatic Arthritis (PsA)¹
(press release)
ZABDENO (Ad26.ZEBOV) and MVABEA (MVA-BN-Filo) – European Commission
Approves Janssen’s Preventive Ebola Vaccine¹
(press release)
DARZALEX (daratumumab) – European Commission (EC) Grants Marketing
Authorisation for Subcutaneous Formulation for all Currently Approved Intravenous
Formulation Indications
(press release)
SIRTURO (bedaquiline) – U.S. FDA Approves New Pediatric Formulation as Part of
Combination Therapy to Treat Children with Pulmonary Multidrug-Resistant
Tuberculosis
(press release)
DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) – U.S. FDA Approves
a new Subcutaneous Formulation of Daratumumab for the Treatment of Patients
with Multiple Myeloma
(press release)
IMBRUVICA (ibrutinib) – U.S. FDA Approves IMBRUVICA Plus Rituximab for
Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
(press release)
Regulatory
Submissions
SIMPONI ARIA (golimumab) – Submission to the U.S. Food and Drug
Administration (FDA) for the Treatment of Polyarticular Juvenile Idiopathic Arthritis
and Juvenile Psoriatic Arthritis
(press release)
Other 	STELARA (ustekinumab) Discontinuation of Phase 3 LOTUS Study in Systemic
Lupus Erythematosus
(press release)
Johnson & Johnson Announces Acceleration of its COVID-19 Vaccine Candidate;
Phase 1/2a Clinical Trial to Begin in Second Half of July
(press release)
Biosense Webster Unveils Late-Breaking Results from PRECEPT Study in Patients
with Persistent Atrial Fibrillation
(press release)
1 Subsequent to the quarter

-- 4 of 17 --

5
FULL-YEAR 2020 GUIDANCE:
Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the Company is
unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses,
acquisition-related expenses and purchase accounting fair value adjustments without unreasonable effort. These items
are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in
accordance with GAAP.
The estimated impact of the COVID-19 pandemic is included in the guidance below.
July 2020 	April 2020
($ in Billions, except EPS)
Adjusted Operational Sales1,2
Change vs. Prior Year (0.8%) – 1.0% 	(3.0%) - 0.5%
Operational Sales 2
Change vs. Prior Year
$81.0 to $82.5
(1.3%) – 0.5%
$79.2 to $82.2
(3.5%) - 0.0%
Estimated Reported Sales 3
Change vs. Prior Year
$79.9 to $81.4
(2.6%) – (0.8%)
$77.5 to $80.5
(5.5%) - (2.0%)
Adjusted Operational EPS (Diluted) 2,4
Change vs. Prior Year
$7.85 to $8.05
(9.6%) - (7.3%)
$7.65 to $8.05
(11.9%) - (7.3%)
Adjusted EPS (Diluted) 3,4
Change vs. Prior Year
$7.75 - $7.95
(10.7%) – (8.4%)
$7.50 to $7.90
(13.6%) - (9.0%)
1 Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures
2 Non-GAAP financial measure; excludes the impact of translational currency
3 Calculated using Euro Average Rate: July 2020 = $1.12 Euro Average Rate: April 2020 = $1.09 (Illustrative purposes only)
4 Non-GAAP financial measure; excludes intangible amortization expense and special items
Other modeling considerations will be provided on the webcast.
WEBCAST INFORMATION:
Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:00 a.m.,
Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting
the Johnson & Johnson website. A replay and podcast will be available approximately two hours after the live webcast
in the Investors section of the Company's website at events-and-presentations.
ABOUT JOHNSON & JOHNSON:
At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward
progress. That’s why for more than 130 years, we have aimed to keep people well at every age and every stage of life.
Today, as the world’s largest and most broadly-based health care company, we are committed to using our reach and
size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind,
body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to
profoundly change the trajectory of health for humanity.

-- 5 of 17 --

6
NON-GAAP FINANCIAL MEASURES:
*Operational sales growth excluding the impact of translational currency, adjusted operational sales growth excluding
the net impact of acquisitions and divestitures and translational currency, as well as adjusted net earnings, adjusted
diluted earnings per share and adjusted operational diluted earnings per share excluding after-tax intangible
amortization expense and special items, are non-GAAP financial measures and should not be considered
replacements for, and should be read together with, the most comparable GAAP financial measures. Except for
guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP
financial measures can be found in the accompanying financial schedules of the earnings release and the Investors
section of the Company's website at quarterly-results.
Copies of the financial schedules accompanying this earnings release are available on the Company’s website at
quarterly-results. These schedules include supplementary sales data, a condensed consolidated statement of
earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information
on Johnson & Johnson, including adjusted income before tax by segment, a pharmaceutical pipeline of selected
compounds in late stage development and a copy of today’s earnings call presentation can also be found in the
Investors section of the Company's website at quarterly-results.
NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS:
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of
1995 regarding, among other things: future operating and financial performance, product development, market position
and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are
based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks
or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson &
Johnson. Risks and uncertainties include, but are not limited to: risks related to the impact of the COVID-19 global
pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented
in response, material delays and cancellations of medical procedures, supply chain disruptions and other impacts to
the business, or on the Company’s ability to execute business continuity plans, as a result of the COVID-19 pandemic,
economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological
advances, new products and patents attained by competitors; challenges inherent in new product research and
development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial
success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the
Company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing
difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls
or regulatory action; significant adverse litigation or government action, including related to product liability claims;
changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health
care cost containment; changes in behavior and spending patterns of purchasers of health care products and services;
financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health
care industry by government agencies. A further list and descriptions of these risks, uncertainties and other factors can
be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 29, 2019, including
in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” in
the Company’s most recently filed Quarterly Report on Form 10-Q and the Company’s subsequent filings with the
Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on
request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of
this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new
information or future events or developments.
Press Contacts: Investor Contacts:
Cristal Downing 	Christopher DelOrefice 	Matthew Stuckley
(732) 524-3283 	(732) 524-2955 	(732) 524-2617
(908) 616-8833 (M)
###

-- 6 of 17 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
Percent Change
2020 	2019 	Total 	Operations 	Currency 	2020 	2019 	Total 	Operations 	Currency
Sales to customers by
segment of business
Consumer Health
U.S. 	1,557	$ 	1,537 	1.3 % 	1.3 	- 	3,297	$ 	2,975 	10.8 % 	10.8 	-
International 	1,739 	2,007 	(13.4) 	(7.4) 	(6.0) 	3,624 	3,887 	(6.8) 	(1.9) 	(4.9)
3,296 	3,544 	(7.0) 	(3.6) 	(3.4) 	6,921 	6,862 	0.9 	3.6 	(2.7)
Pharmaceutical
U.S. 	6,120 	5,783 	5.8 	5.8 	- 	12,181 	11,365 	7.2 	7.2 	-
International 	4,632 	4,746 	(2.4) 	1.4 	(3.8) 	9,705 	9,408 	3.2 	6.7 	(3.5)
10,752 	10,529 	2.1 	3.9 	(1.8) 	21,886 	20,773 	5.4 	7.0 	(1.6)
Medical Devices
U.S. 	1,862 	3,083 	(39.6) 	(39.6) 	- 	4,760 	6,192 	(23.1) 	(23.1) 	-
International 	2,426 	3,406 	(28.8) 	(26.4) 	(2.4) 	5,460 	6,756 	(19.2) 	(16.8) 	(2.4)
4,288 	6,489 	(33.9) 	(32.7) 	(1.2) 	10,220 	12,948 	(21.1) 	(19.8) 	(1.3)
U.S. 	9,539 	10,403 	(8.3) 	(8.3) 	- 	20,238 	20,532 	(1.4) 	(1.4) 	-
International 	8,797 	10,159 	(13.4) 	(9.6) 	(3.8) 	18,789 	20,051 	(6.3) 	(2.9) 	(3.4)
Worldwide 	18,336	$ 	20,562 	(10.8) % 	(9.0) 	(1.8) 	39,027	$ 	40,583 	(3.8) % 	(2.2) 	(1.6)
Note: Percentages have been calculated using actual, non-rounded figures
and, therefore, may not recalculate precisely.
SECOND QUARTER 	SIX MONTHS
Percent Change

-- 7 of 17 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
Percent Change
2020 	2019 	Total 	Operations 	Currency 	2020 	2019 	Total 	Operations 	Currency
Sales to customers by
geographic area
U.S. 	9,539	$ 	10,403 	(8.3) % 	(8.3) 	- 	20,238	$ 	20,532 	(1.4) % 	(1.4) 	-
Europe 	4,063 	4,733 	(14.2) 	(11.5) 	(2.7) 	8,890 	9,342 	(4.8) 	(2.1) 	(2.7)
Western Hemisphere excluding U.S. 	1,133 	1,455 	(22.1) 	(8.9) 	(13.2) 	2,635 	2,958 	(10.9) 	(0.1) 	(10.8)
Asia-Pacific, Africa 	3,601 	3,971 	(9.3) 	(7.7) 	(1.6) 	7,264 	7,751 	(6.3) 	(4.9) 	(1.4)
International 	8,797 	10,159 	(13.4) 	(9.6) 	(3.8) 	18,789 	20,051 	(6.3) 	(2.9) 	(3.4)
Worldwide 	18,336	$ 	20,562 	(10.8) % 	(9.0) 	(1.8) 	39,027	$ 	40,583 	(3.8) % 	(2.2) 	(1.6)
Note: Percentages have been calculated using actual, non-rounded figures
and, therefore, may not recalculate precisely.
SECOND QUARTER 	SIX MONTHS
Percent Change

-- 8 of 17 --

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
Percent
Percent 	Percent 	Increase
Amount 	to Sales 	Amount 	to Sales 	(Decrease)
Sales to customers 	18,336	$ 	100.0 	20,562	$ 	100.0 	(10.8)
Cost of products sold 	6,579 	35.9 	6,940 	33.8 	(5.2)
Gross Profit 	11,757 	64.1 	13,622 	66.2 	(13.7)
Selling, marketing and administrative expenses 	4,993 	27.2 	5,546 	27.0 	(10.0)
Research and development expense 	2,707 	14.8 	2,666 	13.0 	1.5
In-process research and development 	6 	0.0 	- 	-
Interest (income) expense, net 	26 	0.2 	(5) 	0.0
Other (income) expense, net 	24 	0.1 	(1,683) 	(8.2)
Restructuring 	61 	0.3 	57 	0.2
Earnings before provision for taxes on income 	3,940 	21.5 	7,041 	34.2 	(44.0)
Provision for taxes on income 	314 	1.7 	1,434 	6.9 	(78.1)
Net earnings 	3,626	$ 	19.8 	5,607	$ 	27.3 	(35.3)
Net earnings per share (Diluted) 	1.36	$ 	2.08	$ 	(34.6)
Average shares outstanding (Diluted) 	2,665.5 	2,691.7
Effective tax rate 	8.0 % 	20.4 %
Adjusted earnings before provision for taxes and net earnings (1)
Earnings before provision for taxes on income 	5,337	$ 	29.1 	8,614	$ 	41.9 	(38.0)
Net earnings 	4,446	$ 	24.2 	6,950	$ 	33.8 	(36.0)
Net earnings per share (Diluted) 	1.67	$ 	2.58	$ 	(35.3)
Effective tax rate 	16.7 % 	19.3 %
(1) See Reconciliation of Non-GAAP Financial Measures.
SECOND QUARTER
2020 	2019

-- 9 of 17 --

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
Percent
Percent 	Percent 	Increase
Amount 	to Sales 	Amount 	to Sales 	(Decrease)
Sales to customers 	39,027	$ 	100.0 	40,583	$ 	100.0 	(3.8)
Cost of products sold 	13,641 	35.0 	13,555 	33.4 	0.6
Gross Profit 	25,386 	65.0 	27,028 	66.6 	(6.1)
Selling, marketing and administrative expenses 	10,196 	26.1 	10,765 	26.5 	(5.3)
Research and development expense 	5,287 	13.5 	5,524 	13.6 	(4.3)
In-process research and development 	6 	0.0 	890 	2.2
Interest (income) expense, net 	(16) 	0.0 	(2) 	0.0
Other (income) expense, net 	(655) 	(1.7) 	(1,705) 	(4.2)
Restructuring 	119 	0.3 	93 	0.3
Earnings before provision for taxes on income 	10,449 	26.8 	11,463 	28.2 	(8.8)
Provision for taxes on income 	1,027 	2.7 	2,107 	5.1 	(51.3)
Net earnings 	9,422	$ 	24.1 	9,356	$ 	23.1 	0.7
Net earnings per share (Diluted) 	3.53	$ 	3.47	$ 	1.7
Average shares outstanding (Diluted) 	2,671.0 	2,697.0
Effective tax rate 	9.8 % 	18.4 %
Adjusted earnings before provision for taxes and net earnings (1)
Earnings before provision for taxes on income 	12,581	$ 	32.2 	15,481	$ 	38.1 	(18.7)
Net earnings 	10,600	$ 	27.2 	12,611	$ 	31.1 	(15.9)
Net earnings per share (Diluted) 	3.97	$ 	4.68	$ 	(15.2)
Effective tax rate 	15.7 % 	18.5 %
(1) See Reconciliation of Non-GAAP Financial Measures.
SIX MONTHS
2020 	2019

-- 10 of 17 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
(Dollars in Millions Except Per Share Data) 	2020 	2019 	2020 	2019
Net Earnings, after tax- as reported 	$3,626 	$5,607 	$9,422 	$9,356
Pre-tax Adjustments
Intangible Asset Amortization expense 	1,127 	1,118 	2,245 	2,248
Litigation expense, net 	613 	409 	733 	832
IPR&D 	6 	- 	6 	890
Restructuring related 	115 	142 	233 	232
Acquisition and Integration related ¹ 	29 	55 	(933) 	122
Unrealized (gains)/losses on securities 	(533) 	(148) 	(206) 	(306)
Medical Device Regulation 2 	37 	- 	51 	-
Other 	3 	(3) 	3 	-
Tax Adjustments
Tax impact on special item adjustments 3 	(253) 	(230) 	(520) 	(763)
Tax legislation and related impacts 	(324) 	- 	(434) 	-
Adjusted Net Earnings, after tax 	$4,446 	$6,950 	$10,600 	$12,611
Average shares outstanding (Diluted) 	2,665.5 	2,691.7 	2,671.0 	2,697.0
Adjusted net earnings per share (Diluted) 	$1.67 	$2.58 	$3.97 	$4.68
Operational adjusted net earnings per share (Diluted) 	$1.69 	$4.01
Notes:
1
2
3 The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the
above pre-tax special items in arriving at adjusted earnings.
Second Quarter 	Six Months Ended
Acquisition and integration related costs for the six months of 2020 primarily includes a $983M Contingent
Consideration reversal related to the timing of certain developmental milestones associated with the Auris Health
acquisition.
European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company’s previously
registered products. MDR is a replacement of the existing European Medical Devices Directive regulatory framework,
and manufacturers of currently marketed medical devices are required to comply with EU MDR beginning in May
2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not
indicative of on-going operations. The Company has excluded only external third-party regulatory and consulting
costs from its Medical Devices operating segments' measures of profit and loss used for making operating decisions
and assessing performance.

-- 11 of 17 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Consumer Health 	Pharmaceutical 	Medical Devices 	Total
WW As Reported 	(7.0)% 	2.1% 	(33.9)% 	(10.8)%
U.S. 	1.3% 	5.8% 	(39.6)% 	(8.3)%
International 	(13.4)% 	(2.4)% 	(28.8)% 	(13.4)%
WW Currency 	(3.4) 	(1.8) 	(1.2) 	(1.8)
U.S. 	- 	- 	- 	-
International 	(6.0) 	(3.8) 	(2.4) 	(3.8)
WW Operational 	(3.6)% 	3.9% 	(32.7)% 	(9.0)%
U.S. 	1.3% 	5.8% 	(39.6)% 	(8.3)%
International 	(7.4)% 	1.4% 	(26.4)% 	(9.6)%
General Surgery
Advanced Sterilization Products 	0.1 	0.1
U.S. 	0.0 	0.0
International 	0.3 	0.2
Baby Care
Baby Center 	0.3 	0.0
U.S. 	0.7 	0.1
International 	0.0 	0.0
All Other Acquisitions and Divestitures 	0.0 	0.0 	0.1 	0.1
U.S. 	0.0 	0.0 	0.1 	0.0
International 	(0.1) 	0.1 	0.0 	0.0
WW Adjusted Operational 	(3.4)% 	3.9% 	(32.5)% 	(8.8)%
U.S. 	2.0% 	5.8% 	(39.5)% 	(8.1)%
International 	(7.5)% 	1.5% 	(26.1)% 	(9.4)%
Adjusted Operational Sales Growth
SECOND QUARTER 2020 ACTUAL vs. 2019 ACTUAL
Segments
Note: Percentages are based on actual, non-rounded figures and may not sum

-- 12 of 17 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Consumer Health 	Pharmaceutical 	Medical Devices 	Total
WW As Reported 	0.9% 	5.4% 	(21.1)% 	(3.8)%
U.S. 	10.8% 	7.2% 	(23.1)% 	(1.4)%
International 	(6.8)% 	3.2% 	(19.2)% 	(6.3)%
WW Currency 	(2.7) 	(1.6) 	(1.3) 	(1.6)
U.S. 	- 	- 	- 	-
International 	(4.9) 	(3.5) 	(2.4) 	(3.4)
WW Operational 	3.6% 	7.0% 	(19.8)% 	(2.2)%
U.S. 	10.8% 	7.2% 	(23.1)% 	(1.4)%
International 	(1.9)% 	6.7% 	(16.8)% 	(2.9)%
Skin Health / Beauty
Dr. Ci Labo - Japan 	(0.2) 	0.0
U.S. 	0.0 	0.0
International 	(0.4) 	(0.1)
General Surgery
Advanced Sterilization Products 	1.0 	0.4
U.S. 	1.1 	0.4
International 	0.9 	0.4
Baby Care
Baby Center 	0.3 	0.0
U.S. 	0.7 	0.1
International 	0.0 	0.0
All Other Acquisitions and Divestitures 	(0.1) 	0.1 	0.0 	0.0
U.S. 	0.0 	0.1 	0.0 	0.1
International 	(0.2) 	0.0 	0.0 	0.0
WW Adjusted Operational 	3.6% 	7.0% 	(18.8)% 	(1.7)%
U.S. 	11.5% 	7.2% 	(22.0)% 	(0.8)%
International 	(2.5)% 	6.7% 	(15.9)% 	(2.6)%
Note: Percentages are based on actual, non-rounded figures and may not sum
Adjusted Operational Sales Growth
SIX MONTHS 2020 ACTUAL vs. 2019 ACTUAL
Segments

-- 13 of 17 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
SECOND QUARTER 	SIX MONTHS
2020 	2019 	Reported 	Operational (1) Currency 	2020 	2019 	Reported 	Operational (1) Currency
CONSUMER HEALTH SEGMENT (2,3)
BABY CARE
US 	96	$ 	99 	-3.5% 	-3.5% 	- 	188	$ 	186 	1.2% 	1.2% 	-
Intl 	260 	344 	-24.3% 	-16.6% 	-7.7% 	529 	651 	-18.7% 	-12.6% 	-6.1%
WW 	356 	443 	-19.7% 	-13.6% 	-6.1% 	717 	837 	-14.3% 	-9.5% 	-4.8%
ORAL CARE
US 	170 	155 	9.7% 	9.7% 	- 	346 	306 	12.9% 	12.9% 	-
Intl 	227 	234 	-2.8% 	4.0% 	-6.8% 	446 	450 	-0.8% 	4.6% 	-5.4%
WW 	397 	389 	2.2% 	6.3% 	-4.1% 	792 	756 	4.8% 	8.0% 	-3.2%
OTC
US 	627 	484 	29.6% 	29.6% 	- 	1,316 	991 	32.8% 	32.8% 	-
Intl 	522 	580 	-10.1% 	-5.0% 	-5.1% 	1,181 	1,160 	1.8% 	6.0% 	-4.2%
WW 	1,149 	1,064 	7.9% 	10.7% 	-2.8% 	2,497 	2,151 	16.1% 	18.3% 	-2.2%
SKIN HEALTH / BEAUTY(4)
US 	536 	663 	-19.2% 	-19.2% 	- 	1,195 	1,251 	-4.5% 	-4.5% 	-
Intl 	471 	539 	-12.5% 	-8.2% 	-4.3% 	929 	1,041 	-10.7% 	-7.4% 	-3.3%
WW 	1,007 	1,202 	-16.2% 	-14.3% 	-1.9% 	2,124 	2,292 	-7.3% 	-5.8% 	-1.5%
WOMEN'S HEALTH
US 	3 	3 	-2.9% 	-2.9% 	- 	7 	6 	14.3% 	14.3% 	-
Intl 	199 	250 	-20.4% 	-12.0% 	-8.4% 	427 	472 	-9.6% 	-2.1% 	-7.5%
WW 	202 	253 	-20.1% 	-11.8% 	-8.3% 	434 	478 	-9.3% 	-1.9% 	-7.4%
WOUND CARE / OTHER
US 	126 	132 	-4.7% 	-4.7% 	- 	245 	234 	4.7% 	4.7% 	-
Intl 	59 	61 	-2.4% 	3.7% 	-6.1% 	111 	114 	-1.9% 	2.8% 	-4.7%
WW 	185 	193 	-4.0% 	-2.1% 	-1.9% 	356 	348 	2.6% 	4.1% 	-1.5%
TOTAL CONSUMER HEALTH
US 	1,557 	1,537 	1.3% 	1.3% 	- 	3,297 	2,975 	10.8% 	10.8% 	-
Intl 	1,739 	2,007 	-13.4% 	-7.4% 	-6.0% 	3,624 	3,887 	-6.8% 	-1.9% 	-4.9%
WW 	3,296	$ 	3,544 	-7.0% 	-3.6% 	-3.4% 	6,921	$ 	6,862 	0.9% 	3.6% 	-2.7%
See footnotes at end of schedule
% Change 	% Change

-- 14 of 17 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
SECOND QUARTER 	SIX MONTHS
PHARMACEUTICAL SEGMENT (2,5) 2020 	2019 	Reported 	Operational (1) Currency 	2020 	2019 	Reported 	Operational (1) Currency
IMMUNOLOGY
US 	2,362	$ 	2,379 	-0.7% 	-0.7% 	- 	4,772	$ 	4,542 	5.1% 	5.1% 	-
Intl 	1,161 	1,087 	6.8% 	11.0% 	-4.2% 	2,389 	2,175 	9.8% 	13.7% 	-3.9%
WW 	3,523 	3,466 	1.6% 	3.0% 	-1.4% 	7,161 	6,717 	6.6% 	7.9% 	-1.3%
REMICADE
US 	593 	801 	-25.8% 	-25.8% 	- 	1,218 	1,575 	-22.7% 	-22.7% 	-
US Exports (6) 133 	62 	* 	* 	- 	243 	138 	75.7% 	75.7% 	-
Intl 	208 	244 	-14.5% 	-8.7% 	-5.8% 	464 	496 	-6.4% 	-1.6% 	-4.8%
WW 	935 	1,107 	-15.5% 	-14.2% 	-1.3% 	1,925 	2,209 	-12.9% 	-11.8% 	-1.1%
SIMPONI / SIMPONI ARIA
US 	256 	281 	-8.7% 	-8.7% 	- 	528 	544 	-2.9% 	-2.9% 	-
Intl 	289 	282 	2.6% 	6.8% 	-4.2% 	547 	543 	0.8% 	4.8% 	-4.0%
WW 	546 	563 	-3.0% 	-0.9% 	-2.1% 	1,075 	1,087 	-1.1% 	1.0% 	-2.1%
STELARA
US 	1,138 	1,058 	7.5% 	7.5% 	- 	2,355 	1,940 	21.4% 	21.4% 	-
Intl 	558 	499 	11.9% 	15.5% 	-3.6% 	1,161 	1,022 	13.6% 	16.9% 	-3.3%
WW 	1,697 	1,558 	8.9% 	10.1% 	-1.2% 	3,516 	2,963 	18.7% 	19.8% 	-1.1%
TREMFYA
US 	241 	176 	36.7% 	36.7% 	- 	428 	344 	24.4% 	24.4% 	-
Intl 	101 	59 	71.0% 	73.4% 	-2.4% 	210 	108 	94.0% 	97.1% 	-3.1%
WW 	342 	235 	45.4% 	46.0% 	-0.6% 	638 	452 	41.1% 	41.8% 	-0.7%
OTHER IMMUNOLOGY
US 	- 	- 	- 	- 	- 	- 	- 	- 	- 	-
Intl 	3 	3 	11.8% 	21.6% 	-9.8% 	6 	6 	2.7% 	8.4% 	-5.7%
WW 	3 	3 	11.8% 	21.6% 	-9.8% 	6 	6 	2.7% 	8.4% 	-5.7%
INFECTIOUS DISEASES
US 	416 	387 	7.4% 	7.4% 	- 	852 	744 	14.5% 	14.5% 	-
Intl 	463 	475 	-2.5% 	2.6% 	-5.1% 	946 	964 	-1.8% 	2.7% 	-4.5%
WW 	878 	862 	1.9% 	4.7% 	-2.8% 	1,798 	1,708 	5.3% 	7.8% 	-2.5%
EDURANT / rilpivirine
US 	10 	12 	-14.0% 	-14.0% 	- 	22 	24 	-6.9% 	-6.9% 	-
Intl 	246 	198 	24.5% 	27.7% 	-3.2% 	458 	397 	15.4% 	18.4% 	-3.0%
WW 	256 	210 	22.2% 	25.2% 	-3.0% 	480 	421 	14.1% 	17.0% 	-2.9%
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
US 	379 	344 	10.5% 	10.5% 	- 	775 	659 	17.7% 	17.7% 	-
Intl 	130 	191 	-32.0% 	-26.1% 	-5.9% 	314 	399 	-21.4% 	-15.8% 	-5.6%
WW 	510 	535 	-4.7% 	-2.6% 	-2.1% 	1,089 	1,058 	2.9% 	5.0% 	-2.1%
OTHER INFECTIOUS DISEASES
US 	25 	31 	-18.7% 	-18.7% 	- 	54 	61 	-11.2% 	-11.2% 	-
Intl 	87 	86 	1.0% 	8.7% 	-7.7% 	174 	168 	3.8% 	9.4% 	-5.6%
WW 	113 	117 	-4.2% 	1.5% 	-5.7% 	229 	229 	-0.2% 	3.9% 	-4.1%
% Change 	% Change

-- 15 of 17 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
SECOND QUARTER 	SIX MONTHS
2020 	2019 	Reported 	Operational (1) Currency 	2020 	2019 	Reported 	Operational (1) Currency
NEUROSCIENCE
US 	778 	664 	17.4% 	17.4% 	- 	1,526 	1,387 	10.1% 	10.1% 	-
Intl 	809 	875 	-7.6% 	-4.1% 	-3.5% 	1,719 	1,780 	-3.5% 	-0.5% 	-3.0%
WW 	1,587 	1,538 	3.2% 	5.2% 	-2.0% 	3,245 	3,167 	2.5% 	4.1% 	-1.6%
CONCERTA / Methylphenidate
US 	55 	15 	* 	* 	- 	107 	112 	-4.2% 	-4.2% 	-
Intl 	94 	123 	-23.0% 	-20.2% 	-2.8% 	212 	239 	-11.0% 	-8.6% 	-2.4%
WW 	149 	137 	8.7% 	11.2% 	-2.5% 	320 	351 	-8.9% 	-7.2% 	-1.7%
INVEGA SUSTENNA / XEPLION /
INVEGA TRINZA / TREVICTA
US 	576 	506 	13.8% 	13.8% 	- 	1,120 	989 	13.2% 	13.2% 	-
Intl 	303 	312 	-2.8% 	0.3% 	-3.1% 	642 	619 	3.7% 	6.7% 	-3.0%
WW 	879 	818 	7.5% 	8.6% 	-1.1% 	1,762 	1,608 	9.5% 	10.7% 	-1.2%
RISPERDAL CONSTA
US 	74 	81 	-9.3% 	-9.3% 	- 	150 	158 	-4.9% 	-4.9% 	-
Intl 	79 	101 	-21.2% 	-18.1% 	-3.1% 	173 	203 	-14.9% 	-11.9% 	-3.0%
WW 	153 	182 	-15.9% 	-14.2% 	-1.7% 	323 	361 	-10.5% 	-8.9% 	-1.6%
OTHER NEUROSCIENCE
US 	75 	62 	21.5% 	21.5% 	- 	150 	128 	16.8% 	16.8% 	-
Intl 	331 	340 	-2.5% 	1.7% 	-4.2% 	691 	719 	-3.9% 	-0.8% 	-3.1%
WW 	406 	401 	1.2% 	4.7% 	-3.5% 	841 	847 	-0.7% 	1.8% 	-2.5%
ONCOLOGY
US 	1,181 	1,013 	16.6% 	16.6% 	- 	2,356 	1,975 	19.3% 	19.3% 	-
Intl 	1,609 	1,684 	-4.4% 	-0.9% 	-3.5% 	3,448 	3,240 	6.4% 	9.9% 	-3.5%
WW 	2,791 	2,697 	3.5% 	5.7% 	-2.2% 	5,804 	5,215 	11.3% 	13.5% 	-2.2%
DARZALEX
US 	492 	369 	32.9% 	32.9% 	- 	955 	721 	32.3% 	32.3% 	-
Intl 	409 	405 	1.2% 	5.9% 	-4.7% 	883 	682 	29.6% 	34.7% 	-5.1%
WW 	901 	774 	16.3% 	18.8% 	-2.5% 	1,838 	1,403 	31.0% 	33.5% 	-2.5%
ERLEADA
US 	136 	62 	* 	* 	- 	255 	120 	* 	* 	-
Intl 	33 	7 	* 	* 	* 	57 	10 	* 	* 	*
WW 	170 	69 	* 	* 	* 	313 	130 	* 	* 	*
IMBRUVICA
US 	447 	367 	21.5% 	21.5% 	- 	879 	716 	22.6% 	22.6% 	-
Intl 	502 	463 	8.3% 	13.4% 	-5.1% 	1,101 	898 	22.6% 	27.4% 	-4.8%
WW 	949 	831 	14.1% 	17.0% 	-2.9% 	1,980 	1,615 	22.6% 	25.3% 	-2.7%
VELCADE
US 	- 	- 	- 	- 	- 	- 	- 	- 	- 	-
Intl 	98 	224 	-56.1% 	-55.2% 	-0.9% 	206 	487 	-57.7% 	-56.9% 	-0.8%
WW 	98 	224 	-56.1% 	-55.2% 	-0.9% 	206 	487 	-57.7% 	-56.9% 	-0.8%
ZYTIGA / abiraterone acetate
US 	87 	198 	-55.6% 	-55.6% 	- 	226 	383 	-40.9% 	-40.9% 	-
Intl 	480 	500 	-3.9% 	-2.0% 	-1.9% 	1,032 	994 	3.8% 	6.1% 	-2.3%
WW 	568 	698 	-18.6% 	-17.2% 	-1.4% 	1,258 	1,377 	-8.6% 	-7.0% 	-1.6%
OTHER ONCOLOGY
US 	20 	16 	22.9% 	22.9% 	- 	42 	34 	21.4% 	21.4% 	-
Intl 	87 	85 	2.2% 	5.9% 	-3.7% 	169 	169 	-0.3% 	3.3% 	-3.6%
WW 	106 	101 	5.5% 	8.6% 	-3.1% 	210 	203 	3.4% 	6.3% 	-2.9%
PULMONARY HYPERTENSION
US 	545 	439 	24.2% 	24.2% 	- 	1,031 	869 	18.7% 	18.7% 	-
Intl 	243 	251 	-3.3% 	-1.0% 	-2.3% 	503 	477 	5.3% 	7.9% 	-2.6%
WW 	789 	690 	14.2% 	15.0% 	-0.8% 	1,534 	1,346 	13.9% 	14.9% 	-1.0%
OPSUMIT
US 	256 	203 	26.1% 	26.1% 	- 	485 	375 	29.3% 	29.3% 	-
Intl 	150 	146 	3.0% 	5.7% 	-2.7% 	310 	279 	11.2% 	14.1% 	-2.9%
WW 	406 	348 	16.5% 	17.6% 	-1.1% 	795 	654 	21.6% 	22.8% 	-1.2%
UPTRAVI
US 	254 	175 	44.5% 	44.5% 	- 	466 	351 	32.6% 	32.6% 	-
Intl 	28 	28 	4.0% 	7.3% 	-3.3% 	66 	50 	33.6% 	37.6% 	-4.0%
WW 	282 	203 	39.0% 	39.5% 	-0.5% 	532 	401 	32.7% 	33.2% 	-0.5%
OTHER PULMONARY HYPERTENSION
US 	37 	61 	-40.2% 	-40.2% 	- 	81 	143 	-43.5% 	-43.5% 	-
Intl 	64 	78 	-17.6% 	-16.4% 	-1.2% 	126 	149 	-15.1% 	-13.7% 	-1.4%
WW 	101 	140 	-27.5% 	-26.9% 	-0.6% 	207 	292 	-29.0% 	-28.3% 	-0.7%
CARDIOVASCULAR / METABOLISM / OTHER
US 	837 	902 	-7.2% 	-7.2% 	- 	1,643 	1,849 	-11.1% 	-11.1% 	-
Intl 	347 	373 	-7.0% 	-2.4% 	-4.6% 	701 	771 	-9.1% 	-5.6% 	-3.5%
WW 	1,184 	1,275 	-7.1% 	-5.8% 	-1.3% 	2,344 	2,620 	-10.5% 	-9.5% 	-1.0%
XARELTO
US 	559 	549 	1.7% 	1.7% 	- 	1,086 	1,091 	-0.5% 	-0.5% 	-
Intl 	- 	- 	- 	- 	- 	- 	- 	- 	- 	-
WW 	559 	549 	1.7% 	1.7% 	- 	1,086 	1,091 	-0.5% 	-0.5% 	-
INVOKANA / INVOKAMET
US 	132 	132 	-0.8% 	-0.8% 	- 	249 	286 	-13.0% 	-13.0% 	-
Intl 	47 	43 	9.1% 	14.8% 	-5.7% 	105 	92 	14.1% 	18.1% 	-4.0%
WW 	179 	177 	1.6% 	3.1% 	-1.5% 	354 	379 	-6.4% 	-5.5% 	-0.9%
PROCRIT / EPREX
US 	70 	113 	-38.3% 	-38.3% 	- 	146 	261 	-44.1% 	-44.1% 	-
Intl 	66 	70 	-5.0% 	-2.3% 	-2.7% 	145 	148 	-2.2% 	-0.1% 	-2.1%
WW 	136 	183 	-25.6% 	-24.6% 	-1.0% 	291 	409 	-28.9% 	-28.2% 	-0.7%
OTHER
US 	78 	107 	-27.7% 	-27.7% 	- 	163 	211 	-22.9% 	-22.9% 	-
Intl 	234 	260 	-10.2% 	-5.3% 	-4.9% 	451 	531 	-15.0% 	-11.3% 	-3.7%
WW 	312 	368 	-15.3% 	-11.8% 	-3.5% 	614 	742 	-17.3% 	-14.6% 	-2.7%
TOTAL PHARMACEUTICAL
US 	6,120 	5,783 	5.8% 	5.8% 	- 	12,181 	11,365 	7.2% 	7.2% 	-
Intl 	4,632 	4,746 	-2.4% 	1.4% 	-3.8% 	9,705 	9,408 	3.2% 	6.7% 	-3.5%
WW 	10,752	$ 	10,529 	2.1% 	3.9% 	-1.8% 	21,886	$ 	20,773 	5.4% 	7.0% 	-1.6%
See footnotes at end of schedule
% Change 	% Change

-- 16 of 17 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
SECOND QUARTER 	SIX MONTHS
MEDICAL DEVICES SEGMENT (2,5) 2020 	2019 	Reported 	Operational (1) Currency 	2020 	2019 	Reported 	Operational (1) Currency
INTERVENTIONAL SOLUTIONS
US 	255 	366 	-30.5% 	-30.5% 	- 	620 	709 	-12.6% 	-12.6% 	-
Intl 	335 	385 	-12.8% 	-10.9% 	-1.9% 	697 	774 	-9.9% 	-8.0% 	-1.9%
WW 	590 	750 	-21.5% 	-20.5% 	-1.0% 	1,317 	1,482 	-11.2% 	-10.2% 	-1.0%
ORTHOPAEDICS
US 	869 	1,331 	-34.7% 	-34.7% 	- 	2,119 	2,649 	-20.0% 	-20.0% 	-
Intl 	583 	894 	-34.8% 	-32.6% 	-2.2% 	1,371 	1,779 	-22.9% 	-20.6% 	-2.3%
WW 	1,451 	2,224 	-34.7% 	-33.9% 	-0.8% 	3,489 	4,428 	-21.2% 	-20.3% 	-0.9%
HIPS
US 	137 	216 	-36.5% 	-36.5% 	- 	343 	429 	-20.1% 	-20.1% 	-
Intl 	88 	147 	-39.8% 	-37.3% 	-2.5% 	220 	295 	-25.4% 	-22.8% 	-2.6%
WW 	226 	364 	-37.8% 	-36.8% 	-1.0% 	563 	725 	-22.3% 	-21.2% 	-1.1%
KNEES
US 	108 	218 	-50.5% 	-50.5% 	- 	322 	441 	-27.1% 	-27.1% 	-
Intl 	66 	153 	-56.8% 	-55.3% 	-1.5% 	196 	299 	-34.6% 	-32.7% 	-1.9%
WW 	174 	372 	-53.1% 	-52.5% 	-0.6% 	517 	741 	-30.1% 	-29.3% 	-0.8%
TRAUMA
US 	354 	407 	-12.9% 	-12.9% 	- 	761 	824 	-7.6% 	-7.6% 	-
Intl 	198 	265 	-25.2% 	-22.6% 	-2.6% 	445 	533 	-16.5% 	-13.9% 	-2.6%
WW 	553 	672 	-17.8% 	-16.7% 	-1.1% 	1,207 	1,357 	-11.1% 	-10.0% 	-1.1%
SPINE, SPORTS & OTHER
(7)
US 	270 	490 	-45.0% 	-45.0% 	- 	693 	955 	-27.4% 	-27.4% 	-
Intl 	230 	328 	-29.9% 	-27.9% 	-2.0% 	510 	651 	-21.7% 	-19.6% 	-2.1%
WW 	499 	818 	-39.0% 	-38.2% 	-0.8% 	1,202 	1,606 	-25.1% 	-24.3% 	-0.8%
SURGERY
US 	490 	926 	-47.0% 	-47.0% 	- 	1,334 	1,927 	-30.8% 	-30.8% 	-
Intl 	1,060 	1,427 	-25.7% 	-22.6% 	-3.1% 	2,317 	2,821 	-17.9% 	-14.8% 	-3.1%
WW 	1,551 	2,353 	-34.1% 	-32.2% 	-1.9% 	3,651 	4,748 	-23.1% 	-21.3% 	-1.8%
ADVANCED
US 	277 	396 	-30.0% 	-30.0% 	- 	658 	800 	-17.7% 	-17.7% 	-
Intl 	498 	633 	-21.2% 	-18.4% 	-2.8% 	1,065 	1,209 	-11.9% 	-8.9% 	-3.0%
WW 	775 	1,029 	-24.6% 	-22.9% 	-1.7% 	1,723 	2,009 	-14.2% 	-12.4% 	-1.8%
GENERAL
US 	213 	530 	-59.8% 	-59.8% 	- 	676 	1,127 	-40.0% 	-40.0% 	-
Intl 	562 	794 	-29.2% 	-26.0% 	-3.2% 	1,252 	1,612 	-22.4% 	-19.2% 	-3.2%
WW 	775 	1,325 	-41.5% 	-39.5% 	-2.0% 	1,928 	2,739 	-29.6% 	-27.8% 	-1.8%
VISION
US 	248 	461 	-46.1% 	-46.1% 	- 	687 	907 	-24.2% 	-24.2% 	-
Intl 	447 	701 	-36.1% 	-34.8% 	-1.3% 	1,075 	1,383 	-22.3% 	-20.8% 	-1.5%
WW 	695 	1,161 	-40.1% 	-39.3% 	-0.8% 	1,762 	2,290 	-23.0% 	-22.2% 	-0.8%
CONTACT LENSES / OTHER
US 	203 	333 	-39.0% 	-39.0% 	- 	549 	654 	-16.1% 	-16.1% 	-
Intl 	352 	509 	-30.9% 	-29.6% 	-1.3% 	819 	1,011 	-19.0% 	-17.6% 	-1.4%
WW 	554 	842 	-34.1% 	-33.3% 	-0.8% 	1,368 	1,666 	-17.9% 	-17.0% 	-0.9%
SURGICAL
US 	45 	128 	-64.6% 	-64.6% 	- 	138 	253 	-45.3% 	-45.3% 	-
Intl 	96 	191 	-49.9% 	-48.8% 	-1.1% 	256 	371 	-31.0% 	-29.6% 	-1.4%
WW 	141 	319 	-55.8% 	-55.2% 	-0.6% 	394 	624 	-36.8% 	-36.0% 	-0.8%
TOTAL MEDICAL DEVICES
US 	1,862 	3,083 	-39.6% 	-39.6% 	- 	4,760 	6,192 	-23.1% 	-23.1% 	-
Intl 	2,426 	3,406 	-28.8% 	-26.4% 	-2.4% 	5,460 	6,756 	-19.2% 	-16.8% 	-2.4%
WW 	4,288	$ 	6,489 	-33.9% 	-32.7% 	-1.2% 	10,220	$ 	12,948 	-21.1% 	-19.8% 	-1.3%
* Percentage greater than 100% or not meaningful 	(6) Reported as U.S. sales
(1) Operational growth excludes the effect of translational currency 	(7) Previously referred to as Spine & Other
(2) Unaudited
(3) Previously referred to as Consumer
(4) Previously referred to as Beauty
(5) Certain prior year amounts have been reclassified to conform to current year product disclosures
Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and,
therefore, may not recalculate precisely.
% Change 	% Change

-- 17 of 17 --